Arrowhead Pharmaceuticals (ARWR) Income towards Parent Company (2016 - 2025)
Historic Income towards Parent Company for Arrowhead Pharmaceuticals (ARWR) over the last 16 years, with Q4 2025 value amounting to $28.2 million.
- Arrowhead Pharmaceuticals' Income towards Parent Company rose 11611.82% to $28.2 million in Q4 2025 from the same period last year, while for Dec 2025 it was $233.5 million, marking a year-over-year increase of 13595.3%. This contributed to the annual value of $30.1 million for FY2025, which is 10493.92% up from last year.
- As of Q4 2025, Arrowhead Pharmaceuticals' Income towards Parent Company stood at $28.2 million, which was up 11611.82% from $16.1 million recorded in Q3 2025.
- In the past 5 years, Arrowhead Pharmaceuticals' Income towards Parent Company registered a high of $367.8 million during Q1 2025, and its lowest value of -$178.7 million during Q2 2025.
- For the 5-year period, Arrowhead Pharmaceuticals' Income towards Parent Company averaged around -$52.9 million, with its median value being -$67.7 million (2021).
- Per our database at Business Quant, Arrowhead Pharmaceuticals' Income towards Parent Company crashed by 36637.3% in 2024 and then skyrocketed by 38962.8% in 2025.
- Quarter analysis of 5 years shows Arrowhead Pharmaceuticals' Income towards Parent Company stood at -$62.9 million in 2021, then skyrocketed by 33.5% to -$41.8 million in 2022, then plummeted by 223.78% to -$135.4 million in 2023, then dropped by 29.43% to -$175.2 million in 2024, then skyrocketed by 116.12% to $28.2 million in 2025.
- Its Income towards Parent Company was $28.2 million in Q4 2025, compared to $16.1 million in Q3 2025 and -$178.7 million in Q2 2025.